CODEN [USA]: IAJPBB ISSN: 2349-7750

INDO AMERICAN JOURNAL OF
PHARMACEUTICAL SCIENCES
http://doi.org/10.5281/zenodo.2677603

Available online at: http://www.iajps.com *Research Article*

TREATMENT OF VIROLOGICAL RESPONCES IN PATIENTS WITH CHRONIC HEPATITIS C THROUGH SOFOSBUVIR AND RIBAZOLE AS COMPARED TO SOFOSBUVIR AND DECLACAVIR

[1]Dr Ayesha Huma, [2]Dr Tayyaba Zulfiqar, [3]Dr Asma Arshid
[1, 2] DHQ Hospital, Chakwal Pakistan, [3] RHC, Munday, Chakwal Pakistan.

Article Received: March 2019 **Accepted:** April 2019 **Published:** May 2019

Abstract:

Objective: *We aimed in this analysis to predict the virologic activities in patients with chronic hepatitis C through diagnosis by sofosbuvir and daclatasvir as compared to sofosbuvir and ribavirin in tertiary care hospital.*

Study Design: *A potential comparative type of analysis*

Place and Duration: *This analysis was processed at gastroenterology department in Services Hospital, Lahore for the period of one year started from November, 2017 to October, 2018.*

Methodology: *Total of 107 patients of chronic hepatitis C virus with predicted HCV RNA through PCR were treated having age limit from 18 years to 60 years of every gender were enrolled. the separation of all patients was made into two groups in association with diagnosis as in Group A the patients were diagnosed through sofosbuvir in addition of daclatasvir and in group B the patients were treated through sofosbuvir in addition of ribazole. To calculate the viral evaluations the PCR for HCV RNA relative to quantity was processed at the accomplishment of 4^{th} week of RVR, 12^{th} week of EVR, 24^{th} week of ETR and after 24 weeks of SVR accomplishment of diagnosis. Total patients were not observed through the diagnosis and progressed no complexity in accordance with conventional procedures which directs the stoppage of diagnosis were sorted out of the analysis. Total details were stated on the written agreement form.*

Results: *Patients with number of 107 were enrolled with average age of 36.46 ± 11.34 years. Female patients were observed as maximum in number with the percentage of 58.9 %. Patients treated through sofosbuvir in addition of daclatasvir and patients which were treated through sofosbuvir in addition of ribazole were having percentage of 80.4 % and 19.6 % respectively. Sustained viral response, rapid viral load response, early viral load response and end treatment response abbreviated as SVR, RVR, EVR and ETR were instantly mostly kept in Group A in matching with Group B where value of P was 0.004, 0.020, 0.020 and 0.004 accordingly. 18 patients out of 21 patients were kept out in group B. In the average of viral load, no instant variation was observed in the two groups after the accomplishment of diagnosis where the value of P was 0.628.*

Conclusion: *It is gained from this analysis that the two diagnoses presented good effectiveness but diagnosis by sofosbuvir in addition of daclatasvir kept most definite Rapid viral response (RVR), Sustained Viral Response (SVR), End treatment response (ETR) and Early viral response (EVR) as a matching with sofosbuvir in addition of ribazole.*

Keywords: *Sofosbuvir in addition of Ribazole, Sofosbuvir in addition of Daclatasvir, Chronic HCV.*

Corresponding author:
Dr. Ayesha Huma,
DHQ Hospital, Chakwal Pakistan.

QR code

Please cite this article in press Ayesha Huma et al., ***Treatment of Virological Responces in Patients with Chronic Hepatitis C through Sofosbuvir and Ribazole As Compared To Sofosbuvir and Declacavir.,*** *Indo Am. J. P. Sci, 2019; 06(05).*

INTRODUCTION:

The present observation advised that almost 180 million persons in the world are having infections of hepatitis C Virus (HCV) with the maximum values of frequency in Asia and Africa [1,2]. Annually 4 million new diseases take place and above than 3,50,000 persons go to death from liver ailment in association with HCV each year according to the World Health Organization (WHO). Past analysis shown that near about 3 to 4 million persons are freshly diseased every year as an outcome in an approximated death of 3.50,000 per year. The 2nd maximum patient volume is found in Pakistan [3,4]. The basic diagnosis of hepatitis C was a mixture of pegylated interferon alfa and ribavirin for 48 weeks of genotype 1 and for genotype 2 and 3 of 24 weeks since most previous period. The stoppage of diagnosis was endurable expected due to partial usage because of reactions and reason to use a certain treatment as well as due to unusual sustained viral response value [4, 5, 6]. The standard of keen for diagnosing the endurable HCV disease is obtained as an oral mixture of Direct-acting antivirals (DAAs) [7,8]. Values of sustained viral responses at after medication 12th week (SVR12) getting above than percentage of 90.0 % were stated for various medicine mixtures in the clinical treatments by safety profiles greater than those of peginterferon in accordance with schedules. Although, the affiliated medical states can unfavorably react to the healing reactions and make complexities in the clarification of outcomes and advanced liver ailment. Therefore, the patients of such states are mostly under-estimated in clinical treatments and ailment conditions evaluated in clinical diagnosis can vary in significant methods from those gotten verification in insignificant treatments. Programs on the bases of population give a significant balance to verify analyses through the provision of extra details relating to the useful profile and healing hazard of a fresh treatment in a bigger number of people [9]. It is stated that total oral direct-acting intervals (DAAs) usefully medicate the Chronic Hepatitis C Virus disease (HCV) but the complexities and response of various treatments fluctuate. Clearance of virus was accomplished through various schedules that were similar according to statistics. But better SVR values were obtained by 3 times of medicine and sofosbuvir with daclatasvir mixture and most probabilities of failure of an organ especially liver as compared to sofosbuvir and ribavirin mixture [10]. Unpassable details are existing in the history of EVR and RVR of patients which were diagnosed with sofosbuvir in addition of daclatasvir along ribavirin or in absence of ribavirin. Through analysis in accordance with the peg-interferon were maximum matched with EVR and RVR. So, this analysis was processed.

METHODOLOGY:

Total patients of chronic hepatitis C virus with predicted HCV RNA through PCR were treated having age limit from 18 years to 60 years of every gender were enrolled. the separation of all patients was made into two groups in association with diagnosis as in Group A the patients were diagnosed through sofosbuvir in addition of daclatasvir and in group B the patients were treated through sofosbuvir in addition of ribazole. To calculate the viral evaluations the PCR for HCV RNA relative to quantity was processed at the accomplishment of 4th week of RVR, 12th week of EVR, 24th week of ETR and after 24 weeks of SVR accomplishment of diagnosis. Total patients were not observed through the diagnosis and progressed no complexity in accordance with conventional procedures which directs the stoppage of diagnosis were sorted out of the analysis. Total details were stated on the written agreement form. Total patients with co-infection of HBV, CTP score more than 9.0, pregnant and lactating women, haemochromatosis, HCC, Wilson's ailment, eGFR less than 30.0 ml per minute, known infarctions of ribavirin or sofosbuvir, auto-immune hepatitis and depressive disease uncontrolled on diagnosis were not included. CBC and LFT were observed at 2nd week and then each 4 weeks contingent to the outcomes. The patients with specific treatment schedules were sorted in this analysis and the details of taking part cases were gotten through the inclusive distinct records of patients taken as a routine method and was enrolled in the progressed checklists for analysis differences of every analyzed patient. Information was entered in SPSS 20. Average and the Standard deviation SD was evaluated for the differences based on quantity as age. Percentage and ratio were evaluated for category-based information as ratio of hepatitis D virus, qualification and gender. For the matching of ratio of HDV with qualification, age groups and gender, the Chi square examination was processed where the value of P was minimum than 0.05 though to be definite.

RESULTS:

Patients with number of 107 were enrolled with average age of 36.46 ± 11.34 years. Female patients were observed as maximum in number with the percentage of 58.9 % and male patients with the percentage of 41.1 %.

Table No 01: Gender distribution

Gender	Quantity	Percentage
Male	44	41.12%
Female	63	58.88%



According to category the most usual group of age was 18 years to 30 years and 31 years to 40 years with respective percentage of 35.5 % and 31.8 %. Whereas, patients observed with the age of 41 years to 50 years and age more than 50 years with the percentage of 23.4 % and 9.3 % respectively.

Table No 02: Age Wise Group distribution

Age Groups	Quantity	Percentage
18-30 Years	38	35.51%
31-40 Years	34	31.78%
41-50 Years	25	23.36%
> 50	10	09.35%



Most of the patients were observed with normal BMI, overweight and obese with the percentage of 82.2 %, 13.1 % and 1.9 % respectively whereas underweight patients were 2.8 % as per BMI of these patients.

Table No 03: BMI Statistics of the patients

BMI	Quantity	Percentage
Normal	88	82.24%
Overweight	14	13.08%
Obese	02	01.87%
Underweight	03	02.81%



Patients with number of 11 were cirrhotic and the maximum strength was non-cirrhotic with the percentage of 89.7 %.

Table No 04: Cirrhosis Statistics of the patients

Cirrhosis	Quantity	Percentage
Cirrhotic	96	89.72%
Non- Cirrhotic	11	10.28%



Patients treated through sofosbuvir in addition of daclatasvir and patients which were treated through sofosbuvir in addition of ribazole were having percentage of 80.4 % and 19.6 % respectively. Sustained viral response, rapid viral load response, early viral load response and end treatment response abbreviated as SVR, RVR, EVR and ETR were instantly mostly kept in Group A in matching with

Group B where value of P was 0.004, 0.020, 0.020 and 0.004 accordingly. 18 patients out of 21 patients were kept out in group B. Details are shown below in tabular form.

Table No 05: Virological Response According to a Regimen of Treatment

Viral Response	Treatment regimen		P-value
	Sofosbuvir and Declacavir	Sofosbuvir and Ribazole	
Rapid viral load response (RVR)			
Achieved	84	18	0.020
Not Achieved	02	03	
Total	86	21	
Early viral load response (EVR)			
Achieved	84	18	0.020
Not Achieved	02	03	
Total	86	21	
End treatment response (ETR)			
Achieved	84	18	0.004
Not Achieved	02	03	
Total	86	21	
Sustained viral response (SVR)			
Achieved	84	18	0.004
Not Achieved	02	03	
Total	86	21	

In this analysis no definite variation was observed in the average of viral load in two groups after the accomplishment of diagnosis as average viral load of Group A having sofosbuvir in addition of daclatasvir and average of viral load in Group B having sofosbuvir in addition of ribazole was 972.31 ± 185 and 120.40 ± 135.6 respectively where the value of P was 0.628.

Table No 06: Patients Distribution According to Viral After Complete Treatment

Treatment regimen	Quantity	Mean±SD	P-value
Sofosbuvir and Declacavir	86	972.31±185.2	0.628
Sofosbuvir and Ribazole	21	120.40±135.6	

DISCUSSION:

Sofosbuvir diagnosis shows the 1st method to the fresh mode of diagnosis of chronic Hepatitis C patients, unless it is 1st verified direct acting antiviral representatives with the huge inherent blockage and strong action in contradiction of total HCV genotypes [11, 12]. Number of 107 patients were diagnosed moderately by sofosbuvir in addition of daclatasvir and sofosbuvir in addition of ribazole in this analysis. Twice groups presented good effectiveness but patients of Group A presented the definite accomplishment of rapid viral response (RVR), Early

viral load response (EVR), Sustained viral response (SVR) and End treatment response (ETR) as a matching of Group B where the values of P were 0.020, 0.020, 0.040 and 0.040 accordingly. Kutala BK et al stated that the mixture of SOF in addition of DCV presented most effectiveness as a matching of SOF in addition of RBV where the value of P is 0.035. the average age of the patients was average in addition of standard deviation equal to 36.46 ± 11.34 years in this analysis and according to types most usual group of age was 18 year to 30 years with the percentage of 35.5 % and 31 to 40 years with the percentage of 31.8 % [13]. Number of males and females out of all was 296 and 286 with the percentage of 50.9 % and 49.1 % respectively where the value of P was 0.22 stated in an else analysis by Umar M et al [14]. Average age of all participated patients was 40.43 ± 9.622 years. While conflictingly we observed female patients as maximum in number than male patients with the percentage of 58.9 % than 41.1 % respectively. The average age was 49.4 ± 12.1 by males and female patients with frequency of 1.1 with the number of 114 out of 102 stated by an else analysis of Sarwar S et al [15].

In this analysis on the valuation of viral response in according with schedule of diagnosis RVR was gained in twice groups and most gotten definite in group A as matching with group B where the value of P was 0.020. In this analysis Early load EVR was almost accomplished through many patients while definite maximum in the Group A as matching with Group B where the value of P was 0.020. no more information is existing in the history of EVR and RVR of those patients who were diagnosed by sofosbuvir in addition of daclatasvir along ribavirin and in absence of ribavirin. EVR and RVR mostly matched in analysis based on peg-interferon as Mangia et al and Delgard et al presenting maximum RVR in overall number of people with the percentage of 31.0 % to 100.0 % and PPV limiting between 69.0 % to 100.0 % [16,17]. These all analyzations were conducted based on peg-interferon diagnosis to all genotypes distinctly. End treatment response (ETR) accomplished by group A with the number of 85 patients out of 86 patients and just 1 case did not accomplish whereas number of 18 patients accomplished in Group B out of number of 21 patients where the value of P was 0.004 in the present analysis. On the either side in the analysis by Siddique MS et al stated that patients diagnosed by sofosbuvir have presented maximum outcomes with the percentage of 99.5 % accomplishment of RVR, 99.0 % of ETR of diagnosed Patients and 98.5 % of SVR of patients [18]. Maximum values of SVR in patients diagnosed through non-interferon mixtures in genotypes 1 and 2 especially by excellent secure profile and useful results and absence of resistance in cirrhotic and non-cirrhotic were presented by else analysis [19].

In this analysis sustained viral response was almost definitely accomplished by the group A patients such as 85 out of 86 patients and in Group B 18 out of 21 patients. Same like in the analysis of El-Khayat et al stated that sustained viral response at 12 weeks after the completion of diagnosis (SVR12) value was with the percentage of 92.0 % in negative cirrhotic cases and with the percentage of 87.0 % in patients which were diagnosed before [20]. In our analysis SVR with the percentage of 98.7 % that is maximum as matching to other printed analysis, it might be due to in our analysis decompensated cirrhotic cases were excluded. Similar observations were gotten in the analysis of Omar H et al stated that total 95.1 % gained the SVR12 where percentage of 95.4 % between patients diagnosed in absence of RBV and percentage of 94.7 % of patients diagnose in presence of RBV where the value of P was 0.32 [21]. On the other side, Welzel TM et al stated that out of total, SVR12 was attained by 91.2 %, sorting in percentage of 92.0 % of cases diagnosed through DCV in addition of SOF and 89.0 % of patients diagnosed through DCV in addition of combination of SOF and RBV [22]. Shiha G et al stated that SVR12 was accomplished in the patients with the percentage of 96.6% getting 12 weeks of DCV in addition of SOF diagnosis, in patients with the percentage of 95.7 % getting 12 weeks of diagnosis of DCV in addition of combination of SOF and RBV as well as SVR12 value was maximum in non-cirrhotic patients getting DCV in addition of SOF just for 12 weeks or 24 weeks.

CONCLUSION:

It is gained from this analysis that the two diagnoses presented good effectiveness but diagnosis by sofosbuvir in addition of daclatasvir kept most definite Rapid viral response (RVR), Sustained Viral Response (SVR), End treatment response (ETR) and Early viral response (EVR) as a matching with sofosbuvir in addition of ribazole. Whereas no definite variation was the average of viral load in the two groups.

REFERENCES:

1. Karchava M, Sharvadze L, Chkhartishvili N, Nelson K, Gochitashivli N, Gatserelia L et al. IL28B favorable genotype and ultra-rapid viral response as earliest treatment predictors of sustained viral response among Georgian cohort infected with hepatitis C genotype one. European

journal of gastroenterology & hepatology. 2012 Jul;24(7):817.
2. Hepatitis C fact sheet. Geneva: World Health Organization; [Accessed July 13, 2009]. Available from: http://www.who.int/mediacentre/factsheets/fs164/en/
3. Siddique MS, Shoaib S, Saad A, Iqbal HJ, Durrani N. Rapid virological&End treatment response of patients treated with Sofosbuvir in Chronic Hepatitis C. Pakistan journal of medical sciences. 2017 Jul;33(4):813.
4. Messina JP, Humphreys I, Flaxman A, Brown A, Cooke GS, Oliver GP, et al. Global distribution and prevalence of hepatitis c virus genotypes. Hepatology. 2015;61(1):77–87
5. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis,management, and treatment of hepatitis C: an update.Hepatology2009;49(4):1335–74.
6. Hoofnagle JH, Mullen KD, Jones DB, Rustgi V, Di Bisceglie A, Peters M, *et al*. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report. N Engl J Med 1986;315(25):1575–8.
7. Falck-Ytter Y, Kale H, Mullen KD, Sarbah SA, Sorescu L,McCullough AJ. Surprisingly small effect of antiviral treatment in patients with hepatitis C. Ann Intern Med 2002;136(4):288–92.
8. Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology 2002:36(5 Suppl 1):S237–44
9. European Association for Study of Liver. EASL Recommendations on Treatment of Hepatitis C 2015. J Hepatol 2015;63:199–236
10. Holmes JA, Thompson AJ. Interferon-free combination therapies for the treatment of hepatitis C: current insights. Hepat Med 2015;7:51–70
11. Welzel TM, Petersen J, Herzer K, Ferenci P, Gschwantler M, Wedemeyer H, Berg T, Spengler U, Weiland O, van der Valk M, Rockstroh J. Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort. Gut. 2016 Sep 7:gutjnl-2016.
12. Gupta V, Kumar A, Sharma P, Arora A. Newer direct-acting antivirals for hepatitis C virus infection: Perspectives for India. The Indian journal of medical research. 2017 Jul;146(1):23.
13. Marino Z, van BF, Forns X, Berg T. New concepts of sofosbuvirbased treatment regimens in patients with hepatitis C. *Gut.* 2014;63:207-215
14. Cholongitas E, Papatheodoridis GV. Sofosbuvir: a novel oral agent for chronic hepatitis C. Annals of Gastroenterology: Quarterly Publication of the Hellenic Society of Gastroenterology. 2014;27(4):331.
15. Kutala BK, Mouri F, Castelnau C, Bouton V, Giuily N, Boyer N, Asselah T, Marcellin P. Efficacy and safety of sofosbuvir-based therapies in patients with advanced liver disease in a real-life cohort. Hepatic medicine: evidence and research. 2017;9:67.
16. Umar M, Khan SA, Ahmed M, Ambreen S, Minhas ZM, Nazar M. Early predictability of virological response in patients of chronic hepatitis-C with genotype-3, treated with pegylated interferon and ribavirin. Journal of Ayub Medical College Abbottabad. 2014 Dec 1;26(4):559-63.
17. Sarwar S, Khan AA. Sofosbuvir based therapy in Hepatitis C patients with and without cirrhosis: Is there difference? Pakistan journal of medical sciences. 2017 Jan;33(1):37.
18. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R *et al*. Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin forinitial treatment of chronic hepatitis C: a randomisedtrial.Lancet 2001;358:958–65.
19. Zeuzem S, Hultcrantz R, Bourliere M, Goeser T, Marcellin P, Sanchez-Tapias J *et al*. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol 2004;40:993–9.
20. Siddique MS, Shoaib S, Saad A, Iqbal HJ, Durrani N. Rapid Virological &End treatment response of patients treated with Sofosbuvir in Chronic Hepatitis C. Pakistan journal of medical sciences. 2017 Jul;33(4):813.
21. Stedman C. Sofosbuvir, a NS5B polymerase inhibitor in the treatment of hepatitis C: a review of its clinical potential. Therap Adv Gastroenterol. 2014;7(3):131–140.
22. El-Khayat H, Fouad Y, Mohamed HI, El-Amin H, Kamal EM, Maher M, Risk A. Sofosbuvir plus daclatasvir with or without ribavirin in 551 patients with hepatitis C-related cirrhosis, genotype 4. Alimentary pharmacology & therapeutics. 2018 Jan 3.
23. Omar H, El Akel W, Elbaz T, El Kassas M, Elsaeed K, El Shazly H, Said M, Yousif M, Gomaa AA, Nasr A, AbdAllah M. Generic daclatasvir plus sofosbuvir, with or without ribavirin, in treatment of chronic hepatitis C: real-world results from 18 378 patients in Egypt. Alimentary pharmacology & therapeutics. 2018

Feb;47(3):421-31.
24. Welzel TM, Petersen J, Herzer K, Ferenci P, Gschwantler M, Wedemeyer H, Berg T, Spengler U, Weiland O, van der Valk M, Rockstroh J. Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort. Gut. 2016 Sep 7:gutjnl-2016.
25. Shiha G, Soliman R, ElBasiony M, Hassan AA, Mikhail NN. Sofosbuvir plus Daclatasvir with or without ribavirin for treatment of chronic HCV genotype 4 patients: real-life experience. Hepatology international. 2018 Apr 16:1-9.